Clinical trials: Oral Anticoagulants
Atrial Fibrillation
Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
1. The recent development of novel oral anticoagulants (NOACs), including direct thrombin inhibitor (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), could potentially overcome many drawbacks of…
- Trial name
- DARING-AF (NCT02666157)
- Testing
- Dabigatran etexilate, Rivaroxaban, Apixaban
- Where
- 5 sites in Taiwan
- Volunteers
- 3,672 people
- Sponsor
- National Cheng-Kung University Hospital
Behcet Syndrome
Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome
In patients with Behçet's syndrome (BS), deep venous thrombosis (DVT) is thought to result from inflammation of the vessel wall rather than hyper coagulability.
- Trial name
- ACTOR (NCT06780462)
- Testing
- Corticosteroids + Rivaroxaban, Corticosteroids alone
- Where
- 17 sites in France
- Volunteers
- 134 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Stroke
Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy.
AiCure uses artificial intelligence and visual recognition technology to confirm medication ingestion. The software is available as an app and downloaded onto a smart phone.
- Trial name
- NCT02599259
- Testing
- Monitored (M+)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- AiCure
Stroke, Atrial Fibrillation
The Incidence of New-brain Lesions on Brain MRI and Safety Between Edoxaban and Apixaban in Patients with Stroke and Nonvalvular Atrial Fibrillation
This study aims to determine whether there is a difference in brain lesion occurrence and safety when brain MRI is followed up between edoxaban and apixaban in stroke patients with nonvalvular atrial fibrillation through…
- Trial name
- APIXABAN (NCT06864052)
- Testing
- Administration of Apixaban, Administration of Edoxaban
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Ewha Womans University Seoul Hospital
Atrial Fibrillation
Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
The purpose of this study is to compare the risk of major bleeding event among nonvalvular atrial fibrillation patients treated with warfarin, apixaban, dabigatran and rivaroxaban.
- Trial name
- NCT02754154
- Testing
- Warfarin, Apixaban, Dabigatran
- Volunteers
- 321,182 people
- Sponsor
- Bristol-Myers Squibb
Direct Oral Anticoagulants (DOACs), Femoral Fractures
Impact of Treatment With Oral Anticoagulants of Patients With Fractures of the Upper End of the Femur
In 2023, oral anticoagulant treatments (anti Xa: apixaban , rivaroxaban, etc.) are tending to replace anti vitamin K treatments in many medical indications. Their prescription is increasing rapidly in the elderly.
- Conditions
- Direct Oral Anticoagulants (DOACs), Femoral Fractures, Surgery
- Trial name
- ANTI_XA AOD (NCT06382584)
- Testing
- Femoral fracture surgery
- Where
- France
- Volunteers
- 610 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Intracardiac Thrombus, STEMI
Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus
Left ventricular thrombus is found in 10 to 25% of patients with impaired left ventricular function following ST-segment elevation myocardial infarction and up to 20% in dilated cardiomyopathy in observational studies.
- Conditions
- Intracardiac Thrombus, STEMI, Heart Failure
- Trial name
- ARGONAUT (NCT05825573)
- Testing
- Vitamin K antagonist, Direct oral anticoagulant
- Where
- 35 sites in France, Reunion
- Volunteers
- 340 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Acute Major Bleeding
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
This is a multicentre, prospective, randomised, double-blinded, group-sequential, parallel-group, adaptive design, phase 3 study to demonstrate the haemostatic efficacy and safety of four-factor prothrombin complex concentrate…
- Trial name
- NCT04867837
- Testing
- Octaplex
- Where
- 63 sites in United States, Austria and 11 more
- Volunteers
- 100 people
- Sponsor
- Octapharma
Gastrointestinal Hemorrhage, Diabetes Complications
Therapeutic Conflicts and Multimorbidity
Clinical practice guidelines do not take into account multimorbidity and various potential therapeutic conflicts. Identifying and quantifying therapeutic conflicts is crucial in multimorbid patients having more than two acute or…
- Conditions
- Gastrointestinal Hemorrhage, Diabetes Complications, Multimorbidity
- Trial name
- NCT02928939
- Testing
- drug-drug or drug-disease interaction
- Where
- Switzerland
- Volunteers
- 1,101 people
- Sponsor
- University of Zurich
Deep Vein Thrombosis
Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants
ABSTRACT Background The optimal duration of oral anticoagulant treatment in patients with idiopathic venous thromboembolism is still uncertain .
- Trial name
- DACUS (NCT00438230)
- Testing
- Warfarin
- Volunteers
- 250 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
Atrial Fibrillation, Stroke
LAA Excision With AF Ablation Versus Oral Anticoagulants for Secondary Prevention of Stroke
This cohort study aims to evaluate thoracoscopic left atrial appendage excision plus atrial fibrillation ablation versus oral anticoagulants for the prevention of stroke and non-central nervous systemic embolism in patients with…
- Conditions
- Atrial Fibrillation, Stroke, Systemic Embolism
- Trial name
- 5A (NCT02478294)
- Testing
- Thoracoscopic LAA Excision plus AF Ablation, Warfarin or Novel Oral Anticoagulants
- Where
- China
- Volunteers
- 474 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Thromboembolism
Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism
The purpose of this trial is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin as needed (pro re nata - prn) to maintain an International Normalised Ratio (INR)…
- Trial name
- RE-COVER I (NCT00291330)
- Testing
- dabigatran etexilate 150 mg, warfarin (INR 2-3)
- Where
- 250 sites in United States, Argentina and 27 more
- Volunteers
- 2,564 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation, Stroke
IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation
The purpose of this study is to use a decentralized claims database to determine whether education on stroke prevention in atrial fibrillation (AF) among AF patients and their providers can result in increased use of oral…
- Trial name
- IMPACT-AFib (NCT03259373)
- Testing
- Early Patient-Level and Provider-Level Educational Intervention, Delayed Provider-Level Educational Intervention
- Where
- 4 sites in United States
- Volunteers
- 64,666 people
- Sponsor
- Harvard Pilgrim Health Care
Atrial Fibrillation
Decentralized Trial in Atrial Fibrillation Patients
The purpose of this study is to validate an approach to decentralize, or virtualize, the clinical trial experience for enrolled subjects, through the coordinated use of multiple digital health and telehealth technologies.
- Trial name
- DeTAP (NCT04471623)
- Testing
- Use of DeTAP App and Home Devices
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Stanford University
Oral Anticoagulant, Atrial Fibrillation
Laboratory Assessment of the Concentration of Direct Oral Anticoagulants in Patients With Atrial Fibrillation
The incidence of thromboembolic and bleeding event associated with catheter ablation for atrial fibrillation(CAAF) varies from 0.9% to 5% during peri-operative period.
- Conditions
- Oral Anticoagulant, Atrial Fibrillation, Pharmacokinetics and Pharmacodynamics
- Trial name
- LOAF (NCT04684056)
- Volunteers
- 1,864 people
- Sponsor
- Wuhan Asia Heart Hospital
Mechanical Aortic and/or Mitral Valve Replacement Operation
Patient International Normalised Ratio (INR) Self-Testing Program
The aims of the study are to prove correlation between laboratory and patient self-testing (PST) measurements, estimation of INR variability within a target therapeutic zone and frequency of hemorrhagic and/or thromboembolic…
- Trial name
- NCT00925197
- Testing
- INR self-testing program
- Volunteers
- 206 people
- Sponsor
- University Hospital, Clermont-Ferrand
Surgery
Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery
Prospective, open-label clinical trial to evaluate the efficacy and safety of andexanet alfa patients who require urgent surgery that have been anticoagulated with the FXa (activated factor X) inhibitors.
- Trial name
- Annexa-S (NCT04233073)
- Testing
- andexanet alfa
- Where
- 56 sites in United States, Austria and 4 more
- Volunteers
- 10 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Atrial Fibrillation
Perioperative Anticoagulant Use for Surgery Evaluation Study
The aim of the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study, is to establish a safe, standardized protocol for the perioperative management of patients with atrial fibrillation (AF) who are receiving a…
- Trial name
- PAUSE (NCT02228798)
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 3,135 people
- Sponsor
- McMaster University
Oral Antiplatele, Anticoagulant Drugs
Effect of Oral Antiplatelet or Anticoagulant Drugs on Postoperative Bleeding Risk and Venous Closure Rate in Patients With Lower Extremity Varicose Veins After Radiofrequency Ablation
This observational study aims to assess the effect of oral antiplatelet or anticoagulant drugs on key postoperative outcomes in patients with lower extremity varicose veins who have undergone radiofrequency ablation.
- Conditions
- Oral Antiplatele, Anticoagulant Drugs, Lower Extremity Varicose Veins, Radiofrequency Ablation
- Trial name
- NCT07208695
- Testing
- Antiplatelet or Anticoagulant Drugs
- Volunteers
- 40 people
- Sponsor
- Chengdu University of Traditional Chinese Medicine
CPB, Oral Anticoagulant Therapy
Study Use of PPSB-SD and VP-VI in Patients With Anticoagulant Therapy and Undergoing Acute CPB Surgery
The purpose of this study was to study the efficacy of PPSB-SD and VP-VI in patients, who received anticoagulant treatment and who had to undergo acute cardiac surgery with a cardiopulmonary bypass (CPB).
- Trial name
- NCT00151853
- Testing
- PPSB-SD
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Prothya Biosolutions